CaseyLO'ConnellMDFACP
Hematology • Los Angeles, CAClotting Disorder, Myeloproliferative Disorder Hematology-Oncology
Associate Professor of Clinical Medicine, Lawrence & Janice Kelly Chair in Hematology, Director, Gehr CURES Myeloid Malignancies Program
Dr. O'Connell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1441 Eastlake Ave
Los Angeles, CA 90089Phone+1 323-865-3000Fax+1 323-865-0060- Is this information wrong?
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2006 - 2007- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2005 - 2006
- University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2004 - 2005
- University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 2001 - 2004
George Washington University School of Medicine and Health SciencesClass of 2001
Certifications & Licensure
CA State Medical License 2002 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Start of enrollment: 2016 Nov 02
- Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent Start of enrollment: 2017 Apr 20
- Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies Start of enrollment: 2017 Nov 21
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsTranexamic Acid in the Treatment of Refractory Gastrointestinal Arteriovenous Malformation Bleeding in Left Ventricular Assist Device Patients.Michael W. Fong, Noam Morningstar-Kywi, Casey O'Connell, Uzma Qureshi, Emily E. Han> ;Circulation. Heart Failure. 2021 Nov 22
- 2 citationsRuxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.Douglas Tremblay, Lukas Ronner, Nikolai A. Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew T. Kuykendall, Casey O'Connell, Jamile M. Shammo, Angela G. Fleischman, Rube...> ;Leukemia Research. 2021 May 27
- 24 citationsTreatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.Casey O'Connell, Carmen P. Escalante, Samuel Z. Goldhaber, Robert D. McBane, Jean M. Connors, Gary E. Raskob> ;The Oncologist. 2021 Jan 1
- Join now to see all
Abstracts/Posters
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary MyelofibrosisCasey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...Casey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...Casey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patie...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hospital Affiliations
Keck Hospital of USCLos Angeles, California
Los Angeles General Medical CenterLos Angeles, California
USC Norris Comprehensive Cancer CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
